An interventional study of Pain neuroscience education and exercise and Usual Care in Chronic Pain, sponsored by Aveiro University. Completed at 1 site in Portugal. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2022-07-18.
Sponsored by Aveiro University · Not applicable, Interventional, and Other
This study aims to investigate the feasibility of using pain neuroscience education for older adults with chronic pain from primary care services. It will have a group of participants receiving pain neuroscience education and exercise and a group receiving usual care.
2,930 studies on the registry are indexed under Chronic Pain; 701 are open to participants now.
This study's enrollment of 24 is below the median of 60 across 2,161 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →Aveiro University is the lead sponsor of 57 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group will receive an 8-week intervention (1 session per week) of pain neuroscience education and exercise. PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will include mobility, balance and strength exercises.
Other: Pain neuroscience education and exercise
This group will receive usual care administered by general practitioners at primary care.
Other: Usual Care
PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
Usual care delivered at primary care for older adults with pain.
Inclusion rate
ratio between the number of participants included in the study and the total number of people contacted
Time frame: 9 weeks
Refusal rate
ratio between the number of individuals who refused to participate in the study and the number of individuals contacted
Time frame: 9 weeks
Exclusion rate
ratio between the number of individuals excluded for not meeting the inclusion criteria and the total number of individuals contacted
Time frame: 9 weeks
Dropout rate
ratio between the number of participants who abandoned the study and the number of participants who completed the initial assessment
Time frame: 9 weeks
Retention rate
ratio between the number of participants who completed the final assessment and the number of participants who completed the initial assessment
Time frame: 9 weeks
Number of participants reporting adverse events
Self-report of any adverse event perceived as being related to the intervention
Time frame: 9 weeks
Perception of participants towards the intervention structure and content
Semi-structured interviews with participants on the structure and content of the intervention
Time frame: 9 weeks
Pain severity and interference
Assessed using the Brief Pain Inventory questionnaire (range 0-110 and higher values are indicative of higher pain severity and interference)
Time frame: Baseline
Pain severity and interference
Assessed using the Brief Pain Inventory questionnaire (range 0-110 and higher values are indicative of higher pain severity and interference)
Time frame: 9 weeks
Pain severity and interference
Assessed using the Brief Pain Inventory questionnaire (range 0-110 and higher values are indicative of higher pain severity and interference)
Time frame: 6 months
Pain catastrophizing
Assessed using the Pain Catastrophizing Scale (range 0-52 and higher values are indicative of higher pain catastrophizing)
Time frame: Baseline
Pain catastrophizing
Assessed using the Pain Catastrophizing Scale (range 0-52 and higher values are indicative of higher pain catastrophizing)
Time frame: 9 weeks
Pain catastrophizing
Assessed using the Pain Catastrophizing Scale (range 0-52 and higher values are indicative of higher pain catastrophizing)
Time frame: 6 months
Depression
Assessed using the Geriatric Depression Scale (range 0-15 and values of 5 or higher are indicative of depression)
Time frame: Baseline
Depression
Assessed using the Geriatric Depression Scale (range 0-15 and values of 5 or higher are indicative of depression)
Time frame: 9 weeks
Depression
Assessed using the Geriatric Depression Scale (range 0-15 and values of 5 or higher are indicative of depression)
Time frame: 6 months
Fear of movement
Assessed using the TAMPA Scale, which assesses fear of movement (range: 13-52 and higher values are indicative of higher levels of fear of movement)
Time frame: Baseline
Fear of movement
Assessed using the TAMPA Scale, which assesses fear of movement (range: 13-52 and higher values are indicative of higher levels of fear of movement)
Time frame: 6 weeks
Fear of movement
Assessed using the TAMPA Scale, which assesses fear of movement (range: 13-52 and higher values are indicative of higher levels of fear of movement)
Time frame: 6 months
Knowledge of pain neuroscience
Assessed using the pain neurophysiology questionnaire (range 0-19 and higher values are indicative of more knowledge on pain neurophysiology)
Time frame: Baseline
Knowledge of pain neuroscience
Assessed using the pain neurophysiology questionnaire (range 0-19 and higher values are indicative of more knowledge on pain neurophysiology)
Time frame: 9 weeks
Knowledge of pain neuroscience
Assessed using the pain neurophysiology questionnaire (range 0-19 and higher values are indicative of more knowledge on pain neurophysiology)
Time frame: 6 months
Gait velocity
Assessed using the gait velocity test - the time, in seconds, that each participant takes to walk 4 meters
Time frame: Baseline
Gait velocity
Assessed using the gait velocity test - the time, in seconds, that each participant takes to walk 4 meters
Time frame: 9 weeks
Gait velocity
Assessed using the gait velocity test - the time, in seconds, that each participant takes to walk 4 meters
Time frame: 6 months
Postural control
Assessed using the Timed up and go test - the time, in seconds, that it takes to stand from a chair, walk 3 meters, turn, walk another 3 meters to sit in the chair.
Time frame: Baseline
Postural control
Assessed using the Timed up and go test - the time, in seconds, that it takes to stand from a chair, walk 3 meters, turn, walk another 3 meters to sit in the chair.
Time frame: 9 weeks
Postural control
Assessed using the Timed up and go test - the time, in seconds, that it takes to stand from a chair, walk 3 meters, turn, walk another 3 meters to sit in the chair.
Time frame: 6 months
Self-perceived disability
assessed using the World Health Organization Disability Assessment Schedule 2.0 - 12-item version of WHODAS 2.0) questionnaire (range: 12-60 and higher values are indicative of higher levels of disability)
Time frame: Baseline
Self-perceived disability
assessed using the World Health Organization Disability Assessment Schedule 2.0 - 12-item version of WHODAS 2.0) questionnaire (range: 12-60 and higher values are indicative of higher levels of disability)
Time frame: 9 weeks
Self-perceived disability
assessed using the World Health Organization Disability Assessment Schedule 2.0 - 12-item version of WHODAS 2.0) questionnaire (range: 12-60 and higher values are indicative of higher levels of disability)
Time frame: 6 months
Perception of change
Assessed using the Global Perception of Change scale (answer is given using a 7-point likert scale from 1- no change to 7 - a great deal better and a considerable improvement that has made all the difference)
Time frame: 9 weeks
Perception of change
Assessed using the Global Perception of Change scale (answer is given using a 7-point likert scale from 1- no change to 7 - a great deal better and a considerable improvement that has made all the difference)
Time frame: 6 months
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aveiro University